Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SGK1 | O00141 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20837143 | 0.84 | IKBKB (0.43) | IKBKBNOTUML3MBTL1MEN1KMT2A | |
| SCHEMBL20837397 | 0.83 | MAPK14 (0.43) | NOTUML3MBTL1MEN1KMT2A | |
| SCHEMBL2235270 | 0.83 | IKBKB (0.37) | IKBKBNOTUML3MBTL1SGK1 | |
| SCHEMBL20837302 | 0.78 | ENPP1 (0.41) | IKBKBL3MBTL1MEN1KMT2A | |
| SCHEMBL1279682 | 0.75 | IKBKB (0.46) | IKBKBL3MBTL1SGK1MEN1KMT2A | |
| SCHEMBL1846643 | 0.74 | IKBKB (0.50) | IKBKBNOTUML3MBTL1 | |
| SCHEMBL20837303 | 0.73 | ENPP1 (0.48) | IKBKBNOTUML3MBTL1MEN1KMT2A | |
| SCHEMBL20837280 | 0.72 | GAA (0.36) | IKBKBL3MBTL1SGK1MEN1KMT2A | |
| SCHEMBL20837142 | 0.72 | MAPT (0.46) | MEN1KMT2A | |
| SCHEMBL20837311 | 0.71 | KIF11 (0.45) | NOTUML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | ADURO BIOTECH INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | CHINOOK THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| WO-2019055750-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | Aduro Biotech, Inc. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738056-B2 | Pyrazolopyrimidinone compounds and uses thereof | NLRP3, NLRP1, P2RX7 | IKBKB 1662/4885NOTUM 423/4885L3MBTL1 4818/4885 |
| US-20190119285-A1 | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF | NLRP3, NLRP1, P2RX7 | IKBKB 1662/4885NOTUM 423/4885L3MBTL1 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.